Diagnostic test developer KineMed files for a $48 million IPO

By
A A A

KineMed, which develops biomarker tests to measure the progression of diseases, filed on Wednesday with the SEC to raise up to $48 million in an initial public offering. The Emeryville, CA-based company, which was founded in 2001 and booked $7 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol KNMD. KineMed initially filed confidentially on November 18, 2013. H.C. Wainwright, MKM Dillon and Dawson James are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com